Drug Type Antibody drug conjugate (ADC) |
Synonyms L-DOS 47, L-DOS47 |
Target |
Mechanism CEACAM6 inhibitors(Carcinoembryonic antigen related cell adhesion molecule 6 inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H42N6O11 |
InChIKeyFPFZTWMOHOCTJK-NVQXNPDNSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Pancreatic Adenocarcinoma | Phase 2 | US | 11 Dec 2019 | |
Adenocarcinoma of Lung | Phase 2 | PL | 19 Feb 2019 | |
Adenocarcinoma of Lung | Phase 2 | UA | 19 Feb 2019 | |
Non-squamous non-small cell lung cancer | Phase 2 | PL | 01 May 2012 |
Phase 1 | - | 14 | (L-DOS47 0.59 ug/kg in Combination With Pemetrexed and Carboplatin) | rvmtpuiuty(zrovbmjlcw) = ryijgbmwlk uxhxqgavvc (tfjnnmdfsk, pdkbqwuhns - utyrnhheoe) View more | - | 03 Jun 2024 | |
(L-DOS47 0.78 ug/kg in Combination With Pemetrexed and Carboplatin) | rvmtpuiuty(zrovbmjlcw) = hlsmsrrswy uxhxqgavvc (tfjnnmdfsk, lndmqdhtdf - itikggxdlv) View more | ||||||
Phase 1 | 14 | brwxcehofy(jdgwaiprja) = none of the patients experienced a dose limiting toxicity (DLT) qhivzljzuw (stqqqkxvnl ) | Positive | 25 May 2020 | |||
Phase 1/2 | 33 | rlfcuywpix(pwiwnsakqr) = ruepiehccx lgpabmoppa (oyzwzmeybh ) | - | 07 Sep 2015 |